Aptamer Sciences Inc
Aptamer Sciences Inc, a bio venture company, focuses on the Aptamer technology platform for the development of therapeutic and diagnostic platforms. The company's platforms include aptamer discovery, optimization, and the development of therapeutics and diagnostics for cancer and neurological disorders. It offers AlloMAp and Bi-Functional Aptame (BiFAp) platform programs for therapeutics, as well… Read more
Aptamer Sciences Inc (291650) - Total Assets
Latest total assets as of September 2025: ₩25.79 Billion KRW
Based on the latest financial reports, Aptamer Sciences Inc (291650) holds total assets worth ₩25.79 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Aptamer Sciences Inc - Total Assets Trend (2018–2024)
This chart illustrates how Aptamer Sciences Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Aptamer Sciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Aptamer Sciences Inc's total assets of ₩25.79 Billion consist of 58.9% current assets and 41.1% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩11.47 Billion | 35.9% |
| Accounts Receivable | ₩631.31 Million | 2.0% |
| Inventory | ₩21.34 Million | 0.1% |
| Property, Plant & Equipment | ₩10.98 Billion | 34.3% |
| Intangible Assets | ₩938.08 Million | 2.9% |
| Goodwill | ₩961.53 Million | 3.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Aptamer Sciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aptamer Sciences Inc's current assets represent 58.9% of total assets in 2024, a decrease from 93.2% in 2018.
- Cash Position: Cash and equivalents constituted 35.9% of total assets in 2024, down from 89.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 1.0% in 2018.
- Asset Diversification: The largest asset category is cash and equivalents at 35.9% of total assets.
Aptamer Sciences Inc Competitors by Total Assets
Key competitors of Aptamer Sciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Aptamer Sciences Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Aptamer Sciences Inc generates 0.03x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Aptamer Sciences Inc is currently not profitable relative to its asset base.
Aptamer Sciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.84 | 1.03 | 59.51 |
| Quick Ratio | 3.84 | 1.02 | 59.47 |
| Cash Ratio | 0.00 | 0.79 | 0.00 |
| Working Capital | ₩9.63 Billion | ₩ 473.06 Million | ₩ 34.71 Billion |
Aptamer Sciences Inc - Advanced Valuation Insights
This section examines the relationship between Aptamer Sciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.16 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -1.7% |
| Total Assets | ₩31.98 Billion |
| Market Capitalization | $16.41 Million USD |
Valuation Analysis
Below Book Valuation: The market values Aptamer Sciences Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Aptamer Sciences Inc's assets decreased by 1.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Aptamer Sciences Inc (2018–2024)
The table below shows the annual total assets of Aptamer Sciences Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩31.98 Billion | -1.70% |
| 2023-12-31 | ₩32.54 Billion | -28.72% |
| 2022-12-31 | ₩45.65 Billion | +37.23% |
| 2021-12-31 | ₩33.26 Billion | -9.94% |
| 2020-12-31 | ₩36.93 Billion | +343.86% |
| 2019-12-31 | ₩8.32 Billion | -24.28% |
| 2018-12-31 | ₩10.99 Billion | -- |